Remdesivir Has ‘Little Or No Effect’ On COVID-19 Mortality: WHO Study

Written by on October 16, 2020

The antiviral drug remdesivir, considered one of the most promising COVID-19 treatments, turns out to do little to prevent deaths from the disease, according to a WHO-backed study.

Remdesivir, which was part of the experimental cocktail given to US President Donald Trump when he caught the new coronavirus last month, was one of several reviewed in a large study of more than 11,000 people across 30 countries.

The drug “appeared to have little or no effect on hospitalised COVID-19, as indicated by overall mortality, initiation of ventilation, and duration of hospital stay,” said the study posted online late Thursday.

The data, which has yet to be peer-reviewed or published in a scientific journal, seems to contradict at least two major US studies that have shown that remdesivir can reduce the duration of hospital stays for COVID-19 patients.

Washington authorised the emergency use of the medicine, made by US pharmaceutical company Gilead Sciences and originally intended as a treatment for Ebola — on May 1, followed by a range of other countries and the European Union.

 

 

 

-AFP

 

Tagged as


Current track

Title

Artist

Background
Happy New Year!

We take this opportunity to thank you for choosing us. Happy New Year.”

“We are looking forward to serve you with better value added services. 

Thanks for all your support and your valuable interaction in 2020. We hope for a lot many fruitful interactions in 2021.

“May this New Year bring lot of opportunities for us to serve you with greater excellence. Thanks for being our valuable customers. Happy New Year 2021.”

%d bloggers like this: